OBJECTIVE: The efficacy of atomoxetine was assessed in school-age girls with attention-deficit/hyperactivity disorder (ADHD). Atomoxetine is a potent inhibitor of the presynaptic norepinephrine transporter with minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors. METHODS: A total of 291 children who were 7 to 13 years of age and met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for ADHD participated in 1 of 2 combined, double-blind, placebo-controlled, multisite, identical clinical trials. This intent-to-treat subset analysis examined the effects of atomoxetine versus placebo in 51 girls who were randomized toatomoxetine (n = 30) orplacebo (n = 21) for 9 weeks. ADHD symptoms were assessed using parent- and investigator-rated scales. RESULTS:Atomoxetine was superior to placebo on the following measures: the Attention-Deficit Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored Total Score; the Inattentive and Hyperactive/Impulsive subscales of the Attention-Deficit Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored Total Score; the ADHD Index subscale of the Conners' Parent Rating Scale-Revised: Short Form; and the Clinical Global Impressions of Severity of ADHD. Statistically significant efficacy was seen 1 week after randomization and remained so for the duration of the study. One patient from each of the atomoxetine and placebo groups discontinued the study as a result of an adverse event. CONCLUSION:Atomoxetine was found to be effective and well tolerated for the treatment of ADHD in school-age girls.
RCT Entities:
OBJECTIVE: The efficacy of atomoxetine was assessed in school-age girls with attention-deficit/hyperactivity disorder (ADHD). Atomoxetine is a potent inhibitor of the presynaptic norepinephrine transporter with minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors. METHODS: A total of 291 children who were 7 to 13 years of age and met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for ADHD participated in 1 of 2 combined, double-blind, placebo-controlled, multisite, identical clinical trials. This intent-to-treat subset analysis examined the effects of atomoxetine versus placebo in 51 girls who were randomized to atomoxetine (n = 30) or placebo (n = 21) for 9 weeks. ADHD symptoms were assessed using parent- and investigator-rated scales. RESULTS:Atomoxetine was superior to placebo on the following measures: the Attention-Deficit Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored Total Score; the Inattentive and Hyperactive/Impulsive subscales of the Attention-Deficit Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored Total Score; the ADHD Index subscale of the Conners' Parent Rating Scale-Revised: Short Form; and the Clinical Global Impressions of Severity of ADHD. Statistically significant efficacy was seen 1 week after randomization and remained so for the duration of the study. One patient from each of the atomoxetine and placebo groups discontinued the study as a result of an adverse event. CONCLUSION:Atomoxetine was found to be effective and well tolerated for the treatment of ADHD in school-age girls.
Authors: Ziarih Hawi; Natasha Matthews; Edwina Barry; Aiveen Kirley; Joseph Wagner; Robyn H Wallace; Helen S Heussler; Alasdair Vance; Michael Gill; Mark A Bellgrove Journal: Psychopharmacology (Berl) Date: 2012-09-29 Impact factor: 4.530
Authors: Chun-Hyung Kim; Maureen K Hahn; Yoosook Joung; Susan L Anderson; Angela H Steele; Michelle S Mazei-Robinson; Ian Gizer; Martin H Teicher; Bruce M Cohen; David Robertson; Irwin D Waldman; Randy D Blakely; Kwang-Soo Kim Journal: Proc Natl Acad Sci U S A Date: 2006-12-04 Impact factor: 11.205
Authors: Ralf W Dittmann; Peter M Wehmeier; Alexander Schacht; Anette Minarzyk; Martin Lehmann; Kathrin Sevecke; Gerd Lehmkuhl Journal: Child Adolesc Psychiatry Ment Health Date: 2009-08-24 Impact factor: 3.033